Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks

NCT00004330 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

Assess whether chronic administration of gonadotropin-releasing hormone analogues is safe and effective for the prevention of cyclic attacks of acute porphyria in women.

Conditions

  • Porphyria

Interventions

DRUG

luteinizing hormone-releasing factor

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER
  • National Center for Research Resources (NCRR)

    lead NIH

Principal Investigators

  • Karl E Anderson · University of Texas

Study Design

Purpose
PREVENTION

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1987-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004330 on ClinicalTrials.gov